Synapse - Robert Motzer

Results (1252)

Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101

Meeting Abstract

Tomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Miyake, H.; Oya, M.; Albiges, L.; Fujii, Y.; Umeyama, Y.; Wang, J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT)

Meeting Abstract

Rappold, P. M.; Silagy, A. W.; Kuo, F.; Marker, M.; Reising, A.; Millholland, J.; Russo, P.; Coleman, J.; Voss, M. H.; Chan, T. A.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER

Meeting Abstract

Motzer, R. J.; Choueiri, T. K.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Maruzzo, M.; Shah, A. Y.; Suarez, C.; Barrios, C. H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy

Meeting Abstract

Motzer, R. J.; Liu, Y.; Perini, R. F.; Zhang, Y.; Heng, D. Y. C.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)

Meeting Abstract

Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grunwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Kopyltsov, E.; Vidal, M. J. M.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Paclitaxel, ifosfamide & cisplatin (TIP) as second-line therapy for germ cell tumors (GCT):Long-term follow-up and expansion cohort

Meeting Abstract

Gleeson, J. P.; Knezevic, A.; Bromberg, M.; Patil, S.; Sheinfeld, J.; Carver, B. S.; Jones, D. R.; Bains, M. S.; Bajorin, D. F.; Bosl, G. J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial

Meeting Abstract

Cella, D.; Choueiri, T. K.; Blum, S. I.; Ejzykowicz, F.; Hamilton, M.; Zhang, J.; Ivanescu, C.; Motzer, R. J.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma

Meeting Abstract

Carlo, M. I.; Attalla, K.; Patil, S.; Murray, S. J.; Chen, Y. B.; Kotecha, R.; Durack, J. C.; Motzer, R. J.; Hakimi, A. A.; Voss, M. H.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Putative drivers of aggressiveness in TCEB1-mutant renal cell carcinoma: An emerging entity with variable clinical course

Journal Article

DiNatale, R. G.; Gorelick, A. N.; Makarov, V.; Blum, K. A.; Silagy, A. W.; Freeman, B.; Chowell, D.; Marcon, J.; Mano, R.; Sanchez, A.; more...
European Urology Focus (2021)

Fulltext@MSK | Save

Efficacy and safety of atezolizumab plus bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma in IMmotion150: A randomized phase 2 clinical trial

Journal Article

Powles, T.; Atkins, M. B.; Escudier, B.; Motzer, R. J.; Rini, B. I.; Fong, L.; Joseph, R. W.; Pal, S. K.; Sznol, M.; Hainsworth, J.; more...
European Urology (2021)

Fulltext@MSK | Save